Drug repurposing is a fast and consolidated approach for the research of new active compounds bypassing the long streamline of the drug discovery process. Several drugs in clinical practice have been reported for modulating the major Hippo pathway’s terminal effectors, namely YAP (Yes1-associated protein), TAZ (transcriptional co-activator with PDZ-binding motif) and TEAD (transcriptional enhanced associate domains), which are directly involved in the regulation of cell growth and tissue homeostasis. Since this pathway is known to have many cross-talking phenomena with cell signaling pathways, many efforts have been made to understand its importance in oncology. Moreover, this could be relevant to obtain new molecular tools and potential therapeutic assets. In this review, we discuss the main mechanisms of action of the best-known compounds, clinically approved or investigational drugs, able to cross-talk and modulate the Hippo pathway, as an attractive strategy for the discovery of new potential lead compounds.

Repurposing of drugs targeting yap-tead functions / Elisi, Gian Marco; Santucci, Matteo; D’Arca, Domenico; Lauriola, Angela; Marverti, Gaetano; Losi, Lorena; Scalvini, Laura; Bolognesi, Maria Laura; Mor, Marco; Costi, Maria Paola. - In: CANCERS. - ISSN 2072-6694. - 10:9(2018), pp. 329-348. [10.3390/cancers10090329]

Repurposing of drugs targeting yap-tead functions

Elisi, Gian Marco;Santucci, Matteo;D’arca, Domenico;Lauriola, Angela;Marverti, Gaetano;Losi, Lorena;Mor, Marco;Costi, Maria Paola
2018

Abstract

Drug repurposing is a fast and consolidated approach for the research of new active compounds bypassing the long streamline of the drug discovery process. Several drugs in clinical practice have been reported for modulating the major Hippo pathway’s terminal effectors, namely YAP (Yes1-associated protein), TAZ (transcriptional co-activator with PDZ-binding motif) and TEAD (transcriptional enhanced associate domains), which are directly involved in the regulation of cell growth and tissue homeostasis. Since this pathway is known to have many cross-talking phenomena with cell signaling pathways, many efforts have been made to understand its importance in oncology. Moreover, this could be relevant to obtain new molecular tools and potential therapeutic assets. In this review, we discuss the main mechanisms of action of the best-known compounds, clinically approved or investigational drugs, able to cross-talk and modulate the Hippo pathway, as an attractive strategy for the discovery of new potential lead compounds.
2018
10
9
329
348
Repurposing of drugs targeting yap-tead functions / Elisi, Gian Marco; Santucci, Matteo; D’Arca, Domenico; Lauriola, Angela; Marverti, Gaetano; Losi, Lorena; Scalvini, Laura; Bolognesi, Maria Laura; Mor, Marco; Costi, Maria Paola. - In: CANCERS. - ISSN 2072-6694. - 10:9(2018), pp. 329-348. [10.3390/cancers10090329]
Elisi, Gian Marco; Santucci, Matteo; D’Arca, Domenico; Lauriola, Angela; Marverti, Gaetano; Losi, Lorena; Scalvini, Laura; Bolognesi, Maria Laura; Mor, Marco; Costi, Maria Paola
File in questo prodotto:
File Dimensione Formato  
cancers-10-00329.pdf

Open access

Descrizione: Articolo principale
Tipologia: Versione pubblicata dall'editore
Dimensione 5.03 MB
Formato Adobe PDF
5.03 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1167693
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 30
social impact